Benzodiazepines: classification, properties, quantification and monitoring

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review article describes the general characteristics and classification of benzodiazepines, methods of quantitative determination and their area of nitended usage. The effects of benzodiazepines on γ-aminobutyric acid receptors and safety issues are discussed. Information on the pharmacology, metabolism and pharmacogenetics of benzodiazepines is provided. Screening and quantitative methods for determining benzodiazepines, including extraction methods, are presented. In a comparative aspect, the main methods for the quantitative determination of benzodiazepines, enzyme immunoassay and high-performance liquid chromatography with mass spectrometry, are described.

Full Text

Restricted Access

About the authors

I. I. Kuzmin

Research Center for Mental Health

Email: igormir@psychiatry.ru
ORCID iD: 0000-0002-9326-4683
SPIN-code: 1442-0325
Russian Federation, Moscow

O. Yu. Kravtsova

Zakusov Research Institute of Pharmacology

Email: igormir@psychiatry.ru
ORCID iD: 0000-0002-0693-2007
SPIN-code: 1733-2330
Russian Federation, Moscow

A. I. Platova

Research Center for Mental Health

Email: igormir@psychiatry.ru
ORCID iD: 0000-0002-9682-4623
SPIN-code: 6656-2194
Russian Federation, Moscow

I. I. Miroshnichenko

Research Center for Mental Health

Author for correspondence.
Email: igormir@psychiatry.ru
ORCID iD: 0000-0003-4950-5336
SPIN-code: 4117-9703

Dr. Sci. (Med.), Head of Laboratory of Pharmacokinetics

Russian Federation, Moscow

References

  1. Peng L., Morford K.L., Levander X.A. Benzodiazepines and Related Sedatives. Med Clin North Am. 2022;106(1):113–29. doi: 10.1016/j.mcna.2021.08.012.
  2. Herzberg D. Happy Pills in America: From Miltown to Prozac. Baltimore, Johns Hopkins University Press. 2009. 279 р.
  3. Edinoff A.N., Nix C.A., et al. Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurol Int. 2021;13:594–607. doi: 10.3390/neurolint13040059.
  4. Скрябин В.Ю., Застрожин М.С., Брюн Е.А., Сычев Д.А. Бензодиазепиновые транквилизаторы как «золотой стандарт» лечения пациентов с синдромом отмен алкоголя. Современная терапия психических расстройств. 2020; 1:21–8. [Skryabin V.Yu., Zastrozhin M.S., Bryun E.A., Sychev D.A. Benzodiazepine tranquilizers as the “gold standard” for treating patients with alcohol withdrawal syndrome. Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;1:21–8. (In Russ.)]. doi: 10.21265/PSYPH.2020.33.41.003.
  5. Tiglao S.M., Meisenheimer E.S., Oh R.C. Alcohol Withdrawal Syndrome: Outpatient Management. Am. Fam. Physician. 2021;104(3):253–62.
  6. Szatkowska P., Koba M., Koslinski P., et al. Analytical methods for determination of benzodiazepines. A short review. Cent Eur J Chem. 2014;12(10):994–1007. doi: 10.2478/s11532-014-0551-1.
  7. Dubovsky S.L., Marshall D. Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice. Psychother Psychosom. 2022;91:307–34. doi: 10.1159/000524400.
  8. Saari T.I., Uusi-Oukari M., Ahonen J., Olkkola K.T. Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev. 2011;1(63):243 67.
  9. Appenzeller B.M.R., Schneider S., Yegles, M.A., et al. Drugs and chronic 812 alcohol abuse in drivers. Forensic Sci Int. 2005;155:83–90.
  10. Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2012;77:2:295–301. doi: 10.1111/j.1365-2125.2012.04418.x.
  11. Hiemke C., Bergemann N., Clement H., et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsych. 2018;51(01/02):9–62. doi: 10.1055/s-0043-116492.
  12. Xu C., Li C. Y.-T., Kong A.-N.T. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;3(28): 249 68.
  13. Dinis-Oliveira R.J. Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017;49(4):451–63.
  14. Mei V., Concheiro M., Pardi J., Cooper, G. Validation of an LC-MS/MS Method for the Quantification of 13 Designer Benzodiazepines in Blood. J Analyt Toxicol. 2019;43(9):688–95. doi: 10.1093/jat/bkz063.
  15. Samanidou V., Kaltzi I., Kabir A., Furton K.G. Simplifying sample preparation using fabric phase sorptive extraction technique for the determination of benzodiazepines in blood serum by high-performance liquid chromatography. Biomed. Chromatography. 2016; 30(6):829–36.
  16. Bajaj A.O., Ly D., Johnson-Davis K.L. Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. J Mass Spectrom Adv Clin Lab. 2022;24:100–6. doi: 10.1016/j.jmsacl.2022.04.005.
  17. DeFreitas L., Fonseca Pego A.M., Kronstrand R., et al. Fast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry. J Anal Toxicol. 2022;46(8):852–59. doi: 10.1093/jat/bkac044.
  18. Persona K., Madej K., Knihnicki P., Piekoszewski W. Analytical methodologies for the determination of benzodiazepines in biological samples. J Pharmaceut Biomed Anal. 2015;113:239–64. doi: 10.1016/j.jpba.2015.02.017.
  19. Ahmad S.M., Nogueira J.M.F. High throughput bar adsorptive microextraction: A novel cost-effective tool for monitoring benzodiazepines in large number of biological samples. Talanta. 2019;199:195–202. doi: 10.1016/j.talanta.2019.02.004.
  20. Mastrovito R.A., Papsun D.M., Logan B.K. The Development and Validation of a Novel Designer Benzodiazepines Panel by LC-MS-MS. J Anal Toxicol. 2021;45(5):423–28. doi: 10.1093/jat/bkab013.
  21. Sofalvi S., Lavins E.S, Kaspar C.K., et al. Development and Validation of an LC–MS-MS Method for the Detection of 40 Benzodiazepines and Three Z-Drugs in Blood and Urine by Solid-Phase Extraction. J Analyt Toxicol. 2020:1–10. doi: 10.1093/jat/bkaa072.
  22. Мирошниченко И.И., Шилов Ю.Е. Анализ биологических образцов в современной лабораторной практике. Разработка и регистрация лекарственных средств. 2019;8(2)8:115–20. [Miroshnichenko I.I., Shilov Yu.E. Analysis of biological samples in modern laboratory practice. Analysis of biological samples in modern laboratory practice. Razrabotka i registratsiya lekarstvennykh sredstv. 2019;8(2)8:115–20. (In Russ.)]. doi: 10.33380/2305-2066-2019-8-2-115-120.
  23. An J., Dong Z., Zhang W., et al. Development of a simple nanofiber-based solid phase extraction procedure coupled with high performance liquid chromatography analysis for the quantification of eight sedative-hypnotic drugs in human urine samples. Microchem J. 2021;168(27):106475. doi: 10.1016/j.microc.2021.106475.
  24. Xander M.R. Wijk V., Yun C., et al. A Liquid-Chromatography High-Resolution Mass Spectrometry Method for Non-FDA Approved Benzodiazepines. J Analyt Toxicol. 2018:1–5. doi: 10.1093/jat/bky092.
  25. Kimani M., Lanzarotta A., Batson J. Rapid determination of eight benzodiazepines in suspected counterfeit pharmaceuticals using surface-enhanced Raman scattering with handheld Raman spectrometers. J Foren Sci. 2021;66(6):2167–79. doi: 10.1111/1556-4029.14797.
  26. Frey K.A., Koeppe R.A., Holthoff V.A. In Vivo Imaging of Benzodiazepine Receptors with Positron Emission Tomography. In book: SITES of DRUG ACTION in the HUMAN BRAIN. CRC Press. 2020. Р. 29–47. doi: 10.1201/9780367811419-3.
  27. Weinstein E.A., Liu L., Ordonez A.A., et al. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother. 2012;56(12):6284–90. doi: 10.1128/aac.01644-12.
  28. Uddin M.N., Samanidou V.F., Papadoyannis I.N. An Overview on Total Analytical Methods for the Detection of 1,4-Benzodiazepines. Pharm Anal Acta. 2014;5:303. doi: 10.4172/2153-2435.1000303.
  29. Qriouet Z., Qmichou Z., Bouchoutrouch N., et al. Analytical Methods Used for the Detection and Quantification of Benzodiazepines. J Analyt Methods Chem. 2019;2019:11. doi: 10.1155/2019/2035492.
  30. Albishri H.M., Aldawsari N.A., Abd El-Hady D.A. Simple and Reliable Liquid Chromatographic Method for Simultaneous Determination of Five Benzodiazepine Drugs in Human Plasma. Analytica. 2022;3:251–65. Doi: 10.3390/ analytica3020018.
  31. Lotfi S., Veisi H. Electrochemical determination of clonazepam drug based on glassy carbon electrode modified with Fe3O4/R-SH/Pd nanocomposite. Mater. Sci Eng C Mater Biol Appl. 2019;103:109754. doi: 10.1016/j.msec.2019.109754.
  32. Kerrigan S., Mellon M.B., Hinners P. Detection of phenazepam in impaired driving. J Analyt Toxicol. 2013;37:605–10. doi: 10.1093/jat/bkt07.
  33. Chaouali N., Moslah B., Salem K.B., et al. Illicit substances identified in the urine of 11.170 suspected drug users in North Tunisia. Pan Afr Med J. 2021;38:20. doi: 10.11604/pamj.2021.38.20.26781.
  34. Santhosh S.R., Sampath S., Gupta A. Simultaneous analysis of eight benzodiazepines in blood and urine matrix by gas chromatography-mass spectrometry: Implications for air crash investigation. Indian J Aerosp Med. 2019;63(1):2–7.
  35. Nakamura M. Analyses of benzodiazepines and their metabolites in various biological matrices by LC‐MS(/MS). Biomed Chromatogr. 2011;25:1283–307. doi: 10.1002/bmc.1598.
  36. Inoue K., Ozawa Y., Toyooka T. Application of Liquid Chromatography Coupled with Electrospray Ionization Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Sedative Medicine in Clinical Stage. Chromatography. 2015;36:81–92.
  37. Bertol E., Vaiano F., Furlanetto S., Mari F. Cross-reactivities and structure-reactivity relationships of six benzodiazepines to EMIT immunoassay. J Pharmaceut Biomed Anal. 2013;84:168–72.
  38. Feng S., Hess P.R., Wang P., et al. Chapter 13.1 – False-negative results in urine benzodiazepine immunoassay screening. Toxicology Cases for the Clinical and Forensic Laboratory. 2020. Р. 219–21. doi: 10.1016/B978-0-12-815846-3.00051-X.
  39. Mina A., McNeice L., Banukumar S., Vazquez S. Optimisation of Benzodiazepine Immunoassay Using β-Glucuronidase Enzymatic Hydrolysis: A Comparison of Five Different β-Glucuronidase Enzymes. J Biosci Med. 2022;10:7–15. doi: 10.4236/jbm.2022.101002.
  40. Mina A. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty. J Pharmacol Toxicol Methods. 2020;101:106649. doi: 10.1016/j.vascn.2019.106649.
  41. Banaszkiewicz L., Woяniak M.K., Kata M., et al. Rapid and simple multi-analyte LC–MS/MS method for the determination of benzodiazepines and Z-hypnotic drugs in blood samples: Development, validation and application based on three years of toxicological analyses. J Pharm Biomed Anal. 2020;191:113569. doi: 10.1016/j.jpba.2020. 113569.
  42. Мирошниченко И.И. Мониторинг эффективности антипсихотической терапии. Психиатрия. 2022;20(4):128–38. [Miroshnichenko I.I. Monitoring the effectiveness of antipsychotic therapy. Psikhiatriya. 2022;20(4):128–38. (In Russ.)]. doi: 10.30629/2618-6667-2022-20-4-128-138.
  43. Garcia L., Tiscione N.B., Yeatman D.T., Richards-Waugh L. Novel and Nonroutine Benzodiazepines and Suvorexant by LC-MS-MS. J Anal Toxicol. 2021;45(5):462–74. doi: 10.1093/jat/bkaa109.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies